uploads///pills _

Analysts’ Ratings for Enanta Pharmaceuticals and Peers in April

By

Apr. 6 2018, Updated 6:02 p.m. ET

Company overview

Enanta Pharmaceuticals (ENTA) is a biotechnology company with a chemistry-driven approach. The company focuses on creating small molecule drugs mainly for the treatment of viral infections and liver diseases. 

Enanta Pharmaceuticals discovered glecaprevir, a protease inhibitor for the treatment of chronic hepatitis C virus (or HCV). The drug is marketed by AbbVie (ABBV) under the tradename Mavyret in the US and Maviret in other markets. Enanta’s second protease inhibitor under its collaboration with AbbVie is marketed under the tradename Viekera Pak under AbbVie’s initial DAA regimens for the treatment of chronic HCV.

Article continues below advertisement

Analysts’ recommendations

Of the four analysts covering Enanta Pharmaceuticals in April 2018, one analyst gave the stock a “buy” rating while three analysts gave it a “hold” rating. The mean rating for the stock is ~2.8 with a target price of $91.75.

Peer ratings

Of the 20 analysts covering Intercept Pharmaceuticals (ICPT) in April 2018, ten analysts gave the stock a “buy” or a higher rating. Seven analysts gave Intercept a “hold” rating while three analysts gave it a “sell” rating. The mean rating for the stock is 2.5 with a target price of $110.91.

Of the ten analysts covering Acorda Therapeutics (ACOR) in April 2018, three analysts gave the stock a “buy” rating. Six analysts gave it a “hold” rating while one analyst gave it a “sell” rating. The mean rating for the stock is 2.8 with a target price of $24.78.

Of the six analysts covering Conatus Pharmaceuticals (CNAT) in April 2018, two analysts gave the stock a “strong buy” rating while four analysts gave it a “buy” rating. The mean rating for the stock is ~1.7 with a target price of $15.83.

In the next part of this series, we’ll take a look at Enanta Pharmaceuticals’ product pipeline.

Advertisement

More From Market Realist

    • CONNECT with Market Realist
    • Link to Facebook
    • Link to Twitter
    • Link to Instagram
    • Link to Email Subscribe
    Market Realist Logo
    Do Not Sell My Personal Information

    © Copyright 2021 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.